Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

NCT02785939 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

53

Enrollment

NETWORK

Sponsor class

Conditions

CCND1 Gene Amplification
CCND2 Gene Amplification
CCND3 Gene Amplification
CDK4 Gene Amplification
Recurrent Squamous Cell Lung Carcinoma
Stage IV Squamous Cell Lung Carcinoma AJCC v7

Interventions

DRUG: Docetaxel
OTHER: Laboratory Biomarker Analysis
DRUG: Palbociclib

Sponsor

SWOG Cancer Research Network

Collaborators

[object Object]